Neonc Technologies (NASDAQ:NTHI) Posts Quarterly Earnings Results, Misses Estimates By $0.35 EPS

Neonc Technologies (NASDAQ:NTHI) posted its quarterly earnings data on Tuesday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.35), FiscalAI reports.

Neonc Technologies Stock Down 13.1%

NTHI stock opened at $6.09 on Thursday. The business’s 50-day moving average price is $9.05 and its 200-day moving average price is $9.33. Neonc Technologies has a twelve month low of $3.20 and a twelve month high of $15.50.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Zacks Research upgraded shares of Neonc Technologies to a “hold” rating in a research report on Wednesday, January 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Neonc Technologies in a research report on Friday, March 27th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On Neonc Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC boosted its position in shares of Neonc Technologies by 5,314.8% in the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after purchasing an additional 8,982 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Neonc Technologies during the 4th quarter valued at $124,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Neonc Technologies during the 4th quarter valued at $126,000. Royal Bank of Canada purchased a new position in shares of Neonc Technologies during the 1st quarter valued at $247,000. Finally, State Street Corp boosted its holdings in Neonc Technologies by 9.9% in the 4th quarter. State Street Corp now owns 43,170 shares of the company’s stock worth $357,000 after buying an additional 3,900 shares during the period.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.